Claus Bo Svendsen MD, PhD

Claus Bo Svendsen has a diverse range of work experience. Claus Bo is currently serving as an External Evaluator at Innovation Fund Denmark. In addition, Claus is the Owner of S21 Advisory, where they provide consulting services to life science companies and investors, specializing in areas such as clinical development, regulatory strategy, due diligence, and business development.

Prior to their current roles, Claus held various positions at Forward Pharma A/S, a Danish biopharmaceutical company. Claus Bo served as the Chief Executive Officer, leading the company's transformation after a settlement with Biogen. Claus also held the position of Executive Vice President and Vice President of Medical Affairs at Forward Pharma.

Claus co-founded GH Research, a company that they are still actively involved in. Furthermore, they worked at Novo Nordisk as a Global Medical Director, overseeing medical affairs activities related to GLP-1 analogues in obesity and diabetes.

Before joining Novo Nordisk, Claus worked as a Medical Analyst at Nordic Biotech Advisors, where they evaluated drug candidates and conducted due diligence analysis for potential investments. Claus Bo also served as an MD, PhD student at Statens Serum Institut and as a Teaching Assistant at the University of Copenhagen.

Earlier in their career, Claus worked as a Medical Doctor in various disciplines, including internal medicine, neurology, abdominal surgery, and general practice at hospitals and GP practices.

Overall, Claus Bo Svendsen's work experience demonstrates their expertise in the life science industry, particularly in areas such as clinical development, regulatory strategy, and medical affairs.

Claus Bo Svendsen holds a PhD in Chronic Inflammation, Pulmonary Medicine, and Microbiology from the University of Copenhagen, which they obtained from 2006 to 2009. Claus Bo also has a Medical Doctor degree, earned from the University of Copenhagen between 1996 and 2003. In terms of additional certifications, Svendsen has obtained a GMP (Good Manufacturing Practice) Annex 13 certificate from Whitehall Online Training in January 2019, as well as an ICH GCP (Good Clinical Practice) E6 R2 certificate from the same institution during the same period. Claus Bo is also licensed to practice as a physician, having obtained a license from the Danish Board of Health in January 2003 and from Sosialstyrelsen, Sweden (no specific month mentioned) in 2007. Moving forward, Svendsen is pursuing an Executive MBA in Business Administration and Management from Copenhagen Business School, which is expected to be completed from 2022 to 2024.